All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Altimmune Inc. will acquire Spitfire Pharma Inc. and its lead candidate, SP-1373 (to be renamed ALT-801), a GLP-1/glucagon receptor co-agonist for treating nonalcoholic steatohepatitis (NASH).
